Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases
NCT ID: NCT00033254
Last Updated: 2020-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
332 participants
INTERVENTIONAL
2002-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Compare the overall survival of patients with multiple brain metastases treated with radiotherapy with or without thalidomide.
II. Compare the time to tumor progression in patients treated with these regimens.
III. Compare the time to neuro-cognitive progression in patients treated with these regimens.
IV. Compare the cause of death distribution in patients treated with these regimens.
V. Compare the frequency of toxic effects of these regimens in these patients. VI. Evaluate and compare the quality of life of patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to recursive partitioning analysis class (I vs II) and planned chemotherapy after whole brain irradiation (yes vs no). Patients are randomized to 1 of 2 treatment arms.
Arm I: Patients undergo radiotherapy once daily 5 days a week for 3 weeks. Arm II: Patients undergo radiotherapy as in arm I. Beginning on the first day of radiotherapy, patients receive oral thalidomide once daily.
Treatment with thalidomide continues for 2 years in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, at completion of radiotherapy, and then every 2 months for 1 year.
Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 332 patients (166 per treatment arm) will be accrued for this study within 14.5 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I (radiation therapy)
Patients undergo radiotherapy once daily 5 days a week for 3 weeks.
radiation therapy
Undergo conventional radiation therapy
quality-of-life assessment
Ancillary studies
Arm II (radiation therapy, thalidomide)
Patients undergo radiotherapy as in arm I. Beginning on the first day of radiotherapy, patients receive oral thalidomide once daily.
radiation therapy
Undergo conventional radiation therapy
thalidomide
Given orally
quality-of-life assessment
Ancillary studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
radiation therapy
Undergo conventional radiation therapy
thalidomide
Given orally
quality-of-life assessment
Ancillary studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Multiple brain metastases
* At least 1 measurable brain metastasis by MRI
* More than 4.0 cm
* Located in midbrain or brainstem (radiosurgery ineligible)
* Performance status - Zubrod 0-1
* At least 8 weeks
* Absolute neutrophil count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3
* Hemoglobin at least 11 g/dL\*
* Hematocrit at least 35%\*
* Bilirubin no greater than 1.5 mg/dL
* ALT no greater than 2 times normal
* Creatinine no greater than 1.5 mg/dL
* BUN no greater than 25 mg/dL
* No history of deep venous thrombosis
* No sensory neuropathy grade 2 or greater
* No known AIDS
* No other major medical illness or psychiatric impairments that would preclude study therapy
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective barrier method of contraception during and for at least 4 weeks after study
* No prior thalidomide
* More than 2 weeks since prior chemotherapy
* Concurrent chemotherapy allowed if more than 6 weeks past study entry (allowed during first 6 weeks of study if disease progression occurs)
* See Disease Characteristics
* No prior radiotherapy to the head or neck
* No prior radiosurgery
* Prior resection of brain metastases allowed
* No concurrent anticoagulant therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NRG Oncology
OTHER
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonathan Knisely
Role: PRINCIPAL_INVESTIGATOR
Radiation Therapy Oncology Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Radiation Therapy Oncology Group
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RTOG-BR-0118
Identifier Type: -
Identifier Source: secondary_id
CDR0000069268
Identifier Type: -
Identifier Source: secondary_id
NCI-2012-02461
Identifier Type: -
Identifier Source: org_study_id